4Moving Biotech

We are thrilled to announce that Luc Boblet joins 4Moving Biotech as its Chief Executive Officer. Luc Boblet is a seasoned biotech entrepreneur with a demonstrated track record of building biotech ventures. His CEOship includes creating three biotech startups from scratch: Pathoquest, H-IMMUNE, and Egle Therapeutics. He excelled in driving innovation, closing significant fundraising rounds, and forging strategic partnerships. Luc's expertise and passion for bringing positive contributions will be invaluable as we continue to push the boundaries of scientific innovation and growth at 4Moving Biotech. Click here to read the Press Release 👉 :https://lnkd.in/ep9BBHKE #Biotech #Innovation #4MovingBiotech #4P004

Join us for the 18th Annual Conference of the International Society of OsteoArthritis Imaging, scheduled for Wednesday, June 26, 2024, in Marrocco! Professor francis berenbaum, our Chief Medical Officer, will share his expertise on "Synovitis and OA Pain". #IWOAI #osteoarthritis #4movingBiotech #4P004

Découvrez l'interview de Revital Rattenbach, Présidente de 4Moving Biotech dans la dernière édition de BiotechFinances - Medtech - Santé Numérique - DTx - Intelligence Artificielle ! Revital partage des insights précieux sur les dernières avancées de 4Moving Biotech ainsi que sur le développement de notre candidat médicament 4P004 Pour lire l'article 👉 https://lnkd.in/eshfVfxr Un grand merci à Jacques-Bernard Taste et Christine Colmont pour ce grand angle ! #Biotechnologie #Innovation #Leadership #BiotechFinances #Interview #4MovingBiotech #4P004

4Moving Biotech is delighted to announce successful results from its Lasare Phase I 4P004 Clinical Trial intraarticular Liraglutide for knee osteoarthritis patients. The study evaluated the safety, tolerability, and pharmacokinetics of ascending doses of a single intra-articular injection of liraglutide (4P004). The trial reached its primary objective, confirming that intra-articular liraglutide (4P004) was safe and well tolerated. 4P004 is now confidently moving forward to Phase 2 clinical development. Congratulations to our team for this significant achievement! Read the press release 👉 https://lnkd.in/eqkza6hZ #osteoarthritis #4P004 #biotech #frenchtech

We are thrilled to announce that Professor francis berenbaum, Chief Medical Officer of 4Moving Biotech, is invited to speak at the EULAR congress, which will take place from June 12 to 15 in Vienna. Save the date:  🗓️ Date: June 14   🎙️Title of lecture: “ Disease-Modifying OA Drugs: Are We There Yet?”     #EULAR2024 #Rheumatology #ScientificInnovation #DiseaseModifyingOsteoArthritisDrug #biotech #dmoad

The Osteoarthritis Research Society International Congress 2024 will take place in Vienna, Austria, from April 18 to 21. Our Chief Medical Officer, Professor francis berenbaum, is scheduled to deliver an oral presentation on Friday, April 19, 2024. His presentation is titled IN-MOTION: "Pioneering a Phase 2b Clinical Trial Tailored for Inflamed Phenotypes in Knee Osteoarthritis with Intraarticular Liraglutide." Also, Coralie Meurot, our preclinical research scientist, will present her poster titled "Intra-articular Administration of Liraglutide Mitigates Synovial Tissue Alteration and Cartilage Degradation in Preclinical Osteoarthritis Models" during the poster presentation session. #4P004 #clinicaltrial #OARSI #Biotech.

Nous sommes ravis d'annoncer que 4Moving Biotech a été sélectionnée comme l'une des 100 start-up où investir en 2024 par le prestigieux magazine économique Challenges. En tant que jeune start-up, nous sommes fiers de cette reconnaissance. Elle souligne le potentiel unique de notre entreprise à innover dans le domaine de la recherche et du développement d'une solution thérapeutique révolutionnaire pour les personnes atteintes d'arthrose du genou. Nous tenons à exprimer notre reconnaissance à notre formidable équipe, nos partenaires et bien sûr, à vous, notre communauté, pour votre soutien continu.    Pour en savoir plus sur notre vision, notre mission et notre impact, nous vous invitons à consulter l'article complet sur Challenges : 👉  https://lnkd.in/gg6hUbVY     #arthrose #4MovingBiotech #Innovation #StartUp #Biotechnologie #Challenges100StartUp2024 4P-Pharma Voir la traduction

4Moving Biotech is pleased to announce its sponsorship of the Osteoarthritis Research Society International (OARSI) Congress in Vienna, Austria, April 18-21. With more than 30 years of experience serving the OA community, OARSI provides the necessary framework, expert resources, and support for its international members to address the challenges of OA and help improve patient care and outcomes. #Biotech #4P004 #clinicaltrial #OARSI

[#ourcommitments] 2023 has been optimistic for our company. We are pleased to share some of our achievements. 🇫🇷 We were one of the four French startups nominated by the US Prix Galien 2023 committee in the "Best Startup" category 👉https://lnkd.in/e-yGV7q6 ➡️ We announced the completion of patient recruitment for our Phase I clinical trial for patients with knee osteoarthritis 👉 https://lnkd.in/edEXqBwt ➡ 4Moving Biotech announced establishing an international Scientific Advisory Board in anticipation of its knee osteoarthritis drug candidate's phase 2b clinical trial: 👉https://lnkd.in/e_7iHN9g We want to thank all our collaborators, partners and supporters. We are confident that 2024 will be an impactful year. #biotech #innovation #4P004 #liraglutide #glp1

4Moving Biotech wishes you an incredible year of 2024 filled with success, achievement, and unforgettable moments.